Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (97)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Craft, P. S.
Right arrow Articles by Harris, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Craft, P. S.
Right arrow Articles by Harris, A. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:305-311, 1994
© 1994 European Society for Medical Oncology

review-article

Clinical prognostic significance of tumour angiogenesis

P. S. Craft and A. L. Harris

Imperial Cancer Research Fund Molecular Oncology Laboratory, Institute of Molecular Medicine, University of Oxford Oxford, U.K.

Correspondence to: Prof. A. L. Harris, M.D., Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX3 7IJ, U.K.

BACKGROUND:: The importance of tumour angiogenesis in the process of tumour growth and metastasis has recently gained wide acceptance. This has lead to intense investigation into the biology of tumour angiogenesis and its clinical significance. An understanding of angiogenesis may allow therapeutic modulation in order to interrupt the progression from tumourigenesis to metastatic disease and control growth of distant metastases.

DESIGN:: A review was undertaken of studies relating clinical outcome to the assessment of tumour angiogenesis in patients with cancer.

RESULTS:: Studies have been recently reported in a variety of tumours, particularly early breast cancer and melanoma. Quantitative pathology, using microvessel counting, has been the main method applied. However assessment of angiogenic growth factors may provide an alternative. In early breast cancer many studies have shown a worse prognosis for those patients with highly vascular tumours. The prognostic influence of tumour angiogenesis is independent of conventional prognostic indicators. Similar, although more varied results, have been obtained in studies of melanoma and other tumour types.

CONCLUSION:: Tumour angiogenesis, as assessed with quantitative pathology, is an important prognostic indicator in early breast cancer and possibly in other tumour types. Further confirmatory studies are required before this indicator is routinely used to guide treatment selection. Assessment of tumour angiogenesis will be increasingly important in the investigation of new therapies aimed at inhibiting angiogenesis or targeting tumour vasculature.

angiogenesis, prognosis, breast cancer, melanoma, microvessel counts


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
R. Clarijs, L. Schalkwijk, D. J. Ruiter, and R. M. W. de Waal
Lack of Lymphangiogenesis Despite Coexpression of VEGF-C and Its Receptor Flt-4 in Uveal Melanoma
Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1422 - 1428.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
T. Etoh, H. Inoue, S. Tanaka, G. F. Barnard, S. Kitano, and M. Mori
Angiopoietin-2 Is Related to Tumor Angiogenesis in Gastric Carcinoma: Possible in Vivo Regulation via Induction of Proteases
Cancer Res., March 1, 2001; 61(5): 2145 - 2153.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
H. M. W. Verheul, K. Hoekman, F. Lupu, H. J. Broxterman, P. van der Valk, A. K. Kakkar, and H. M. Pinedo
Platelet and Coagulation Activation with Vascular Endothelial Growth Factor Generation in Soft Tissue Sarcomas
Clin. Cancer Res., January 1, 2000; 6(1): 166 - 171.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
M. Takahama, M. Tsutsumi, T. Tsujiuchi, K. Nezu, K. Kushibe, S. Taniguchi, Y. Kotake, and Y. Konishi
Enhanced Expression of Tie2, Its Ligand Angiopoietin-1, Vascular Endothelial Growth Factor, and CD31 in Human Non-Small Cell Lung Carcinomas
Clin. Cancer Res., September 1, 1999; 5(9): 2506 - 2510.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
A. J E Foss, I. A Cree, P. J Dolin, and J. L Hungerford
Modelling uveal melanoma
Br. J. Ophthalmol., May 1, 1999; 83(5): 588 - 594.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
A. A. Alvarez, H. R. Krigman, R. S. Whitaker, R. K. Dodge, and G. C. Rodriguez
The Prognostic Significance of Angiogenesis in Epithelial Ovarian Carcinoma
Clin. Cancer Res., March 1, 1999; 5(3): 587 - 591.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
W. G. Roberts, J. Delaat, M. Nagane, S. Huang, W. K. Cavenee, and G. E. Palade
Host Microvasculature Influence on Tumor Vascular Morphology and Endothelial Gene Expression
Am. J. Pathol., October 1, 1998; 153(4): 1239 - 1248.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
K. R. Dover and A. W. Valley
Review : Angiogenesis: A new target for antineoplastic therapy
Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1): 43 - 60.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.